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Objectives The purpose of this study was to evaluate the feasibility and safety of the combined
outcome of carotid artery stenting (CAS) and coronary artery bypass graft (CABG) surgery in neuro-
logically symptomatic patients.
Background The risk of perioperative stroke in patients undergoing CABG who report a prior his-
tory of transient ischemic attack or stroke has been associated with a 4-fold increased risk as com-
pared to the risk for neurologically asymptomatic patients. It seems appropriate to offer prophylactic
carotid endarterectomy to neurologically symptomatic patients who have signiﬁcant carotid artery
disease and are scheduled for CABG. The CAS-CABG outcome for symptomatic patients remains un-
derreported, notwithstanding randomized data supporting CAS for high-risk patients.
Methods In a prospective, single-center study, the periprocedural and long-term outcomes of 57
consecutive patients who underwent CAS before cardiac surgery were analyzed.
Results The procedural success rate of CAS was 98%. The combined death, stroke, and myocardial
infarction rate was 12.3%. The death and major stroke rate from time of CAS to 30 days after car-
diac surgery was 3.5%. The myocardial infarction rate from time of CAS to 30 days after cardiac sur-
gery was 1.5%.
Conclusions This is the ﬁrst single-center study reporting the combined outcome of CAS-CABG in
symptomatic patients. The periprocedural complication rate and long-term results of the CAS-CABG
strategy in this high-risk population support the reliability of this approach. In such a high-risk pop-
ulation, this strategy might offer a valuable alternative to the combined surgical approach; however,
a large randomized trial is clearly warranted. (J Am Coll Cardiol Intv 2011;4:1190–6) © 2011 by the
American College of Cardiology Foundation
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1191Optimal treatment of patients with concurrent carotid and coro-
nary artery disease remains debatable despite more than 100
publications during the last 30 years (1–3). Stroke is still a major
noncardiac complication of coronary artery bypass graft (CABG)
surgery, with an absolute incidence of 2%. Carotid artery disease
has been associated with an increased risk of perioperative stroke
after CABG, rising from 3% in predominantly asymptomatic
patients with unilateral 50% to 99% stenosis, to 5% in those with
See page 1197
bilateral 50% to 99% stenosis, and 7% to 11% in patients
with carotid occlusion (1,4,5). Moreover, the risk of peri-
operative stroke in CABG patients who report a prior
history of transient ischemic attack (TIA) or stroke has been
associated with a 4-fold increased risk as compared to the
risk for neurologically asymptomatic patients (8.5% [95%
confidence interval (CI): 4.9 to 12.1] versus 2.2% [95% CI:
1.4 to 3.1]) (1). Therefore, it seems appropriate to offer
prophylactic carotid endarterectomy (CEA) to neurologi-
cally symptomatic patients undergoing CABG who have
significant carotid artery disease (2,6–8).
The findings from the SAPPHIRE (Stenting and An-
gioplasty With Protection in Patients at High Risk for End-
arterectomy) trial, including patients with significant cardiac
disease, showed that among high-risk patients with severe
carotid artery stenosis and coexisting conditions, carotid artery
stenting (CAS) using an emboli-protection device is not
inferior to CEA (9,10). The CAS-CABG outcome for symp-
tomatic patients remains underreported, notwithstanding these
randomized data supporting CAS for high-risk patients. In the
available data describing the CAS or CEA-CABG strategy,
periprocedural event rates of the symptomatic and the asymp-
tomatic patients are scarcely reported separately. We report the
results of CAS and subsequent cardiac surgery in 57 patients
with symptomatic carotid artery disease.
Methods
Patient population. In a prospective, nonrandomized study,
e entered 57 consecutive symptomatic patients scheduled
or CAS and cardiac surgery between December 1998 and
anuary 2008.
Patients were considered symptomatic if an ipsilateral
arotid territory stroke or TIA had occurred within 4
onths before the procedure. A carotid artery stenosis was
onsidered significant when a diameter reduction of at least
0% on duplex and an angiographic stenosis of more than
0% (using the quantitative coronary analysis technique) of
he luminal diameter was measured in the common carotid
rtery, internal carotid artery, or at the bifurcation according
o the NASCET (North American Symptomatic Carotid
ndarterectomy Trial) criteria (11,12). 2The indications for cardiac surgery were symptomatic
documented myocardial ischemia) severe coronary artery
isease (including bypass failure) not eligible for percutane-
us revascularization, symptomatic valve disease, and dis-
ase (aneurysm or dissection) of the ascending aorta or arch
hat demanded reconstructive surgery. Exclusion criteria
ncluded: severe renal impairment (serum creatinine 300
mol/l), peripheral vascular disease precluding femoral
artery access, major neurological deficit or any other illness
impeding informed consent, severe diffuse atherosclerosis of
the common carotid artery, chronic total occlusions, long
pre-occlusive lesions (“string sign” lesions). All patients gave
written informed consent. This registry was approved by the
ethical committee of our hospital.
Endpoint deﬁnition. The primary endpoint of the present
tudy was the combined incidence of death, all strokes, and
yocardial infarction (MI) from time of CAS to 30 days
fter cardiac surgery. Secondary endpoints were MI rate and
eath and major stroke rate from time of CAS to 30 days
fter cardiac surgery. In the long-term outcome, cumu-
ative event rates at 5 years are
eported.
Strokes were considered dis-
bling (major) if patients had a
odified Rankin score of more
han 3 at 30 days after onset of
ymptoms. A minor stroke was
efined as a Rankin score of 3 or
ess that resolved completely
ithin 30 days (13). The diag-
osis of Q-wave MI, evaluated
y an independent cardiologist,
as based on the presence of
cute chest pain, new Q waves
n the electrocardiogram, and an elevated creatine kinase to
t least 2 the upper limit of the normal range with an
levated level of MB isoenzyme. In the absence of patho-
ogical Q waves, the diagnosis of non–Q-wave MI was
ased on the increase of creatine kinase level to more than
wice the upper limit of the normal range with an elevated
evel of MB isoenzyme. In our institution, cardiac enzymes
re drawn routinely every 8 h during the first 24 h after each
rocedure. A 12-lead electrocardiogram was performed in
ll patients following CAS and cardiac surgery. The elec-
rocardiogram was performed daily during the first 48 h
ollowing cardiac surgery and in case of unexplained chest
ain during the remaining period of hospitalization.
ardio-cerebrovascular mortality was reported separately
nd was defined as death related to a cardiac or neurological
vent (14).
CAS procedure and subsequent cardiac surgery. Carotid
tenting has been performed following the highest stan-
ard of care using a distal embolic protection device since
Abbreviations
and Acronyms
CABG  coronary artery
bypass graft
CAS  carotid artery
stenting
CEA  carotid
endarterectomy
CI  confidence interval
MI  myocardial infarction
TIA  transient ischemic
attack002. Cardiac surgery (including coronary artery bypass,
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1192valve, or reconstructive surgery of the ascending aorta)
was usually scheduled at least 3 weeks after CAS, unless
clinical instability dictated otherwise. The approach in
our institution for this staged strategy has been described
earlier (14). All patients were clinically evaluated before
the procedure, during the procedure, and immediately
afterward by an impartial neurologist. Before and after
CABG, the same neurologist examined the patients once
more. In case of a major stroke, the patient was moni-
tored afterward in the stroke unit. All patients were
evaluated by this neurologist at an outpatient clinic after
1 and 3 months.
It is our practice to perform CAS (with dual antiplatelet
therapy) and then to stop the clopidogrel 7 days before
CABG (aspirin continued). Clopidogrel is restarted (mean
time of 2 days) after recovery from surgery. In those patients
requiring urgent cardiac surgery, CAS is performed using
dual antiplatelet therapy, which is not stopped before the
cardiac procedure.
Statistical analysis. Proportions are expressed as percentage
and continuous data are expressed as mean  SD. For
right-censored data (i.e., time to event), the Kaplan-
Meier method was used to compute the long-term
survival, stroke, and MI outcomes with corresponding
95% CI. The log-rank test was used to compare groups.
For 95% CI, exact calculations are used (no asymptotic
approximations). For all computations, R software (version
2.12, the R Foundation for Statistical Computing, Vienna,
Austria) was used.
Results
Patient characteristics. The baseline clinical characteristics
of all patients are shown in Table 1. The median waiting
time between the last neurological event and the CAS
procedure was 36 days (interquartile range: 6 to 90 days).
Angiographic and stenting results. CAS was performed
predominantly in the proximal internal carotid artery (n 
52), but it also included the distal (n  3) and proximal
without involvement of the ostium) (n  2) common
arotid artery. In 2 patients, concomitant left subclavian
tenosis or occlusion was treated with angioplasty and
tenting. A distal cerebral protection device was used in 29
atients (50.9%) before 2002, and since 2002, in all patients.
The mean angiographic degree of stenosis was reduced
rom 86  4% to 4  9%. We used a variety of peripheral
r carotid stents: 5 Carotid Wall (Boston Scientific, Natick,
assachusetts), 48 Acculink (Guidant/Abbott, Natick,
assachusetts), 3 NexStent (Boston Scientific), and 1
mnilink (Guidant/Abbott).
Cardiac surgery results. The median time interval between
CAS and cardiac surgery was 28 days (interquartile range:
12 to 58 days). In the present series, 52 patients (91.2%)
underwent CABG, in whom 4 procedures (7%) were accom-plished without cardiopulmonary bypass, 3 patients (5%)
had valve surgery combined with CABG, and 2 (3.5%)
underwent reconstructive surgery of the ascending aorta.
Eight (14%) of the cardiac interventions were redo proce-
dures (second or third). Although the latter group is
exposed to a higher risk for cardiovascular complications, we
included these patients because they represent a substantial
group of patients treated in our daily practice. No major
bleeding requiring rethoracotomy was reported in those
patients on dual antiplatelet therapy versus those on acetyl-
salicylic acid alone during surgery.
Periprocedural outcome and 30-day follow-up. Periprocedural
event rates after CAS and after cardiac surgery are listed in
Table 2. During the period between CAS and surgery, 1
patient suffered a MI and 4 patients had a minor stroke of
which one was contralateral. Cardiac surgery was performed
in 57 patients. One patient who suffered from a MI while
waiting for CABG died 3 months after CABG. One patient
died (cardiac-related) and 1 patient suffered a major stroke
within 30 days after cardiac surgery. In the latter patient,
post-procedural duplex ultrasonography was performed and
showed adequate stent apposition in the treated carotid
artery without hemodynamically significant restenosis or
stent thrombosis. Male and female patients had similar
periprocedural complication rates.
Long-term follow-up. Overall median follow-up was 50
months, with 33% of the patients being followed for 60
months. There were 18 deaths (31.6%): 8 (14%) were
cardiac-related (2 unknown deaths were considered as
cardiac); 2 (3.5%) were neurological deaths; and 8 (11.8%)
died of other causes. No repeat carotid intervention for
restenosis was necessary. On duplex follow-up in 50 patients
Table 1. Baseline Clinical Patient Characteristics (N  57)
Age, yrs 69.7 8.4
Female 19 (33.3)
Hypertension 36 (62)
Diabetes mellitus 8 (14)
Hypercholesterolemia 31 (54.4)
Smoking 11 (19.3)
Previous myocardial infarction 16 (28.1)
Valvular heart disease 14 (24.6)
Congestive heart failure 3 (5.4)
Unstable angina pectoris 21 (36.8)
Previous CABG 8 (14)
Previous PCI 7 (12.3)
Previous CEA 1 (1.8)
Major stroke 3 (5.3)
Minor stroke 12 (21.1)
TIA 42 (73.7)
Values are mean SD or n (%).
CABG  coronary artery bypass graft; CEA  carotid endarterectomy; PCI  percutaneous
coronary intervention; TIA transient ischemic attack.(between 3 and 6 months), 4 moderate restenoses (50% to
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 4 , N O . 1 1 , 2 0 1 1 Van der Heyden et al.
N O V E M B E R 2 0 1 1 : 1 1 9 0 – 6 CAS and CABG in Symptomatic Patients
119365%) were detected. None of these patients had symptoms
related to the treated hemisphere. There was 1 late minor
stroke and 1 late major stroke. No MI occurred.
A univariate analysis showing the cumulative 5-year event
rates is depicted in Table 3. The survival at 5 years was
63.7% (95% CI: 51.3% to 79.1%). The freedom from all
deaths, all strokes, or MI is 56.7% (see Kaplan-Meier curve
in Fig. 1). The all-cause mortality and the all-death,
all-stroke, and MI rates were significantly higher in patients
75 years of age than in those 75 years of age.
Table 2. Periprocedural Outcome After Staged CAS and Cardiac Surgery
Event
CAS
Patients
(n  57)
Cardiac Surgery
Patients
(n  57)
Total
(N  57)
All deaths 0 1 (1.5) 1 (1.5)
Cardiac deaths 0 1 (1.5) 1 (1.5)
Neurological deaths 0 0 0
Nonneurological/noncardiovascular
deaths
0 0 0
All strokes* 4 (7.0) 1 (1.5) 5 (8.8)
Major strokes 0 1 (1.5) 1 (1.5)
Minor strokes 4 (7.0)* 0 4 (7.0)
All MIs 1 (1.5) 0 1 (1.5)
All deaths and major strokes 0 2 (3.5) 2 (3.5)
All deaths, all strokes, and MIs 5 (8.8) 2 (3.5) 7 (12.3)
Values are n (%). *Three ipsilateral and 1 contralateral strokes.
MImyocardial infarction.
Table 3. Cumulative 5-Year Event Rates (Univariate
All-cause mortality
Cardio-cerebrovascular mortality
MI
Major stroke
Minor stroke
All-cause mortality  minor  major stroke
Cardio-cerebrovascular mortality (unknown included)  ma
All-cause mortality  all strokes  MIs
Age 75 yrs
Age 75 yrs
Symptoms 30 days
Symptoms 30 days
Without distal protection device
With distal protection device
All-cause mortality: men
All-cause mortality: women
All-cause mortality: age 75 yrs
All-cause mortality: age 75 yrs
All-cause mortality: without distal protection device
All-cause mortality: with distal protection deviceCI confidence interval; MImyocardial infarction.Discussion
It is considered appropriate to offer prophylactic CEA to
CABG patients who have unilateral or bilateral significant
carotid artery stenosis if they describe a history of TIA or
stroke, especially if the index event was within the preceding
6 months. D’Agostino et al. (8) reported a periprocedural
stroke rate of 17.9% in patients with unilateral carotid
disease and 26.3% in those with bilateral disease undergoing
isolated CABG. These patients have a very high risk of
stroke during CABG, and prophylactic intervention can be
justified. In the present study, we report the periprocedural
complication rates and long-term results of the CAS-
CABG strategy in symptomatic patients.
In some systematic reviews, the 30-day stroke rates have
been evaluated and varied from 2.7% after staged CEA-CABG
(57% asymptomatic) to 4.2% after staged CAS-CABG
(87% asymptomatic), 4.6% after synchronous CEA-CABG (59%
asymptomatic) and 6.3% after reverse staged CABG-CEA
(no detailed data available describing the neurological sta-
tus) (2,6,7). It is difficult to compare the outcome in
symptomatic patients to such data. However, Timaran et al.
(15) described the outcome for the symptomatic subpopu-
lation in a large study based on the NIS (Nationwide
Inpatient Sample) databases of 27,084 patients undergoing
either synchronous CEA-CABG or staged CAS-CABG in
the United States between 2000 and 2004. Stratified anal-
yses according to the symptomatic status and type of carotid
is)
Cumulative Event Rate
at 5 Years (%) 95% CI p Value
36.3 20.9–48.7
21.0 7.9–32.2
1.8 0.0–5.3
6.1 0.0–14.5
9.0 1.1–16.2
43.3 27.4–55.7
ke 22.5 9.2–33.8
35.4 16.9–49.9 0.02
56.9 25.0–75.3
45.6 16.6–64.5 0.97
42.8 21.9–58.1
32.6 11.2–48.9 0.12
55.4 28.0–72.3
37.2 18.6–51.5 0.88
31.6 4.2–51.1
27.3 10.0–41.2 0.01
53.9 21.1–73.1
32.6 11.2–48.9 0.49
39.6 14.5–57.3Analys
jor stro
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1194revascularization revealed that among 973 patients with
symptomatic carotid stenosis, 96.4% underwent CEA-
CABG, and post-operative stroke occurred in 14.2%. Only
25 patients with symptomatic carotid stenosis in this series
underwent CAS-CABG, and the post-operative stroke rate
was 44%. As expected, this reported event rate after CEA-
CABG (14.1%) for the symptomatic subpopulation is
higher than for the above-mentioned group of mainly
asymptomatic patients (2,6,7). However, the 5-fold in-
creased risk of post-operative stroke (44%) for the CAS-
CABG approach compared with those undergoing CEA-
CABG (odds ratio: 4.7; 95% CI: 2.1 to 10.6; p  001) is
striking. Given the small number of patients undergoing
CAS-CABG, This comparison should be interpreted cau-
tiously. In contrast to these findings, we report a favorable
30-day all-stroke rate of 8.8% and a combined risk for
death, all strokes, and MI of 12.3% for the CAS-CABG
approach. One possible explanation for the lower peripro-
cedural combined risk in the present study compared with
the Timaran data may be related to the fact that patients
underwent cardiac surgery without discontinuation of aspi-
rin, whereas clopidogrel was administered until 7 days
before the operations. The balance between the optimal
antiplatelet therapy required for CAS and not postponing
CABG seems to influence this outcome favorably (16).
Furthermore, the high volume of CAS procedures in our
Figure 1. Kaplan-Meier Curve: 5-Year Freedom From All Deaths,
All Strokes, and MIs
n indicates number at risk. Data represent Kaplan-Meier curve for patients
free from any death, stroke, and myocardial infarction (MI) during follow-
up. Percentage on the right of the black line represent the freedom from
all deaths, all strokes, or MI at 5 years.center could account for these favorable short-term resultsof the combined procedure. The low periprocedural MI rate
of 1.5% emphasizes the reduced invasiveness of this ap-
proach, which is especially important for these high-risk
patients. No statistical difference was found when these
CAS results before CABG are compared with the cumula-
tive incidence of the primary endpoint at 30 days in the
SAPPHIRE trial for the symptomatic patients (8.8% vs.
2.1% SAPPHIRE CAS, p  0.212 and 9.3% SAPPHIRE
CEA, p  0.18).
The long-term follow-up showed a survival rate of 63.7%
with a significantly higher all-cause mortality rate and
all-death, stroke, and MI rate for patients 75 years.
We report a 12.3% stroke rate at 3 years, which was not
statistically different from the subgroup analyses for symp-
tomatic patients in the SAPPHIRE study (12.3% [7 of 57
patients] vs. 6.0% [3 of 50 patients] in the SAPPHIRE
CAS group (p  0.331) and vs. 8.7% [4 of 46 patients] in
the SAPPHIRE CEA group, p  0.751), taking into
account that in our study, all patients underwent CABG,
whereas in the SAPPHIRE population, only a minority had
coexisting severe coronary artery disease (9,10).
Whether or not the 3% rule for isolated CEA can be
achieved in such a high-risk population remains uncertain.
However, undertaking a CAS procedure with a 3%
complication rate in asymptomatic patients and 6% in
symptomatic patients should remain the goal of all inter-
ventionists (17,18). Patients with recent onset neurological
symptoms may pose an additional problem. They face the
highest risk of stroke in the first few weeks of the index
event, and CAS or CEA may have to be performed with the
acceptance that the procedural risk will be higher (19).
Delaying the intervention might reduce the procedural risk,
but it lessens the benefit of intervening because of the
number of strokes that occur while waiting.
Finally, we conducted both crude and propensity score–
adjusted comparisons for the periprocedural outcome be-
tween this patient group and the asymptomatic population
planned for CABG in our center. When analyzing the
baseline clinical patient characteristics from this study and
the asymptomatic population, we found clinically compara-
ble groups (Table 4). The periprocedural outcome for both
groups is shown in Table 5. The stroke rate, as expected, is
lower for the asymptomatic patients (3.1% vs. 8.8%, p 
0.05). A short-term propensity score weighting was not
applicable due to a low periprocedural event rate. To adjust
long-term survival for symptomatic versus asymptomatic
patients for differences in baseline characteristics, we used
propensity score–weighted Cox proportional hazards mod-
eling. Long-term survival depends on being symptomatic or
not. The crude hazard ratio for death is 1.62 (95% CI: 0.94
to 2.77) on average for the first 5 years after CABG for
symptomatic patients versus asymptomatic patients. After
propensity score–weighting (accounting for sex, age, hyper-
tension, diabetes, smoking, hypercholesterolemia, prior
C
p
m
t
t
t
g
A
w
t
a
r
s
d
r
s
a
a
r
t
C
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 4 , N O . 1 1 , 2 0 1 1 Van der Heyden et al.
N O V E M B E R 2 0 1 1 : 1 1 9 0 – 6 CAS and CABG in Symptomatic Patients
1195valve disease, prior MI, prior congestive heart failure, and
prior CEA), the adjusted hazard ratio is 1.65 (95% CI: 1.17
to 2.33). Therefore, symptomatic patients have worse long-
term survival with a hazard ratio of 1.65, which cannot be
explained by difference in baseline characteristics.
Study limitations. Only 4 patients underwent off-pump
ABG. Therefore, a meaningful comparison with on-
ump CABG or CEA–off-pump CABG could not be
ade (20).
Analyzing the latest natural history data, it becomes clear
hat about 40% of all strokes occur within the first 24 h after
he index event. Therefore, a much earlier carotid interven-
ion should be planned after symptoms (21). Current
uideline documents from the American Heart Association/
merican Stroke Association recommend surgery within 2
eeks of symptom onset (22). These assumptions were not
aken into account in our institution until recently. It might
lso be expected that the periprocedural CAS complication
ates will rise when intervening in an earlier phase.
When interpreting the data from Timaran et al. (15), one
hould take into account the ascertainment bias in the NIS
atabase for strokes after CAS. In the United States,
eimbursement for CAS depends on being enrolled in a
tudy. Therefore, all patients are carefully examined before
nd after therapy by a neurologist. Very few CEA patients
re examined by an independent neurologist. Thus, the
eporting may not be equal and could make CAS look worse
han CEA.
Table 4. Single-Center Baseline Clinical Patient Characteristics for
Symptomatic and Asymptomatic Patients Planned for CAS-CABG
Asymptomatic
Patients
(n  356)
Symptomatic
Patients
(n  57) p Value
Age, yrs 72.9 7.7 69.7 8.4 0.01
Female 104 (28.6) 19 (33.3) 0.53
Hypertension 164 (45.1) 36 (62) 0.02
Diabetes mellitus 81 (22.2) 8 (14) 0.17
Hypercholesterolemia 157 (43.1) 31 (54.4) 0.15
Smoking 72 (19.8) 11 (19.3) 0.99
History of neurological symptoms 58 (15.9)
Previous MI 117 (32.1) 16 (28.1) 0.54
Valvular heart disease 88 (24.2) 14 (24.6) 0.99
Congestive heart failure 46 (12.6) 3 (5.4) 0.12
Unstable angina pectoris 141 (38.8) 21 (36.8) 0.77
Previous CABG 47 (12.9) 8 (14) 0.83
Previous PTCA 47 (12.9) 7 (12.3) 0.99
Previous carotid angioplasty 7 (1.9)
Previous CEA 16 (4.4) 1 (1.8) 0.49
Values are mean SD or n (%).
CAS carotid artery stenting; PTCA percutaneous transluminal coronary angioplasty;other abbreviations as in Tables 1 and 2.onclusions
We report the outcome of CAS-CABG in symptomatic
patients. The periprocedural complication rate and long-
term results of the CAS-CABG strategy in this high-risk
population support the reliability of this approach. In such
a high-risk population, this strategy might offer a valuable
alternative to the combined surgical approach; however, a
large randomized trial is clearly warranted.
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